# To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference

> **NCT06091436** · PHASE3 · COMPLETED · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 176 (actual)

## Conditions studied

- Infertility

## Interventions

- **DRUG:** GenSci094
- **DRUG:** Placebo RecFSH / follitropin alfa
- **BIOLOGICAL:** Biological: RecFSH / Follitropin alfa (Days 1 to 7)
- **DRUG:** Placebo GenSci094
- **BIOLOGICAL:** RecFSH / Follitropin alfa (Days 8 to hCG)
- **DRUG:** Ganirelix
- **BIOLOGICAL:** hCG
- **DRUG:** Progesterone

## Key facts

- **NCT ID:** NCT06091436
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-24
- **Primary completion:** 2023-12-25
- **Final completion:** 2024-01-29
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2024-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06091436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06091436, "To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06091436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*